Mononucleotide Autologous Stem Cells and Demineralized Bone Matrix in the Treatment of Non Union/Delayed Fractures
|ClinicalTrials.gov Identifier: NCT01435434|
Recruitment Status : Unknown
Verified March 2014 by Hadassah Medical Organization.
Recruitment status was: Not yet recruiting
First Posted : September 16, 2011
Last Update Posted : March 4, 2014
|Condition or disease||Intervention/treatment||Phase|
|Non Union/Delayed Fractures||Device: the Sepax is a tool to standardize adult stem cell. Ignite ®ICS injectable scaffold manufactured by Wright Medical Technology.||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
Experimental: sepax, ignite, fracture healing
the mesenchymal cells will be separated by sepax separation system and demineralized bone matrix will be done using IGNITE INJECTABLE REPAIR GRAFT
Device: the Sepax is a tool to standardize adult stem cell. Ignite ®ICS injectable scaffold manufactured by Wright Medical Technology.
- clinical and radiological bony union at 3 months and 6 months.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01435434
|Contact: Hadas Lemberg, PhD||00 972 2 email@example.com|
|Not yet recruiting|